We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Predicts Survival in Liver Cancer Patients

By LabMedica International staff writers
Posted on 20 Sep 2024

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and ranks as the fourth leading cause of cancer-related deaths worldwide. More...

For patients with advanced HCC, several systemic treatments are available that travel through the bloodstream to target cancer cells throughout the body. One such treatment involves the combination of the drugs atezolizumab and bevacizumab, known as Atezo/Bev therapy, which is generally recommended as the first-line treatment for liver cancer. However, there are currently no reliable markers to predict the therapy’s effectiveness. Researchers have now discovered that serum autoantibody levels may serve as a predictive marker for treatment response in liver cancer patients.

In a recent study, a research team from Okayama University (Okayama, Japan) investigated the use of anti-PD1 autoantibodies as a prognostic marker for cancer. To identify a reliable marker for predicting treatment efficacy, the researchers focused on autoantibodies—antibodies produced by the immune system that target the body’s own proteins. These autoantibodies have been found in various types of cancer and can be easily detected in blood serum, making them promising biomarker candidates. The researchers hypothesized that anti-PD-1 autoantibodies could influence the effectiveness of Atezo/Bev therapy, as they target the same cellular pathways as atezolizumab.

To test this hypothesis, the researchers conducted a study involving 63 patients with advanced HCC who received Atezo/Bev therapy. They measured the levels of anti-PD-1 autoantibodies in the patients’ blood serum both before and after treatment, analyzing the relationship between these levels and the patients’ treatment outcomes. Their findings, published in Gastro Hep Advances, revealed a statistically significant correlation between higher levels of anti-PD-1 autoantibodies and lower survival rates. This suggests that anti-PD-1 autoantibodies could serve as a potential biomarker for predicting the response to immune checkpoint inhibitors, including atezolizumab, in patients with HCC. However, further research is needed to better understand the biological role of these autoantibodies in cancer immunotherapy.

“Ours is the first study to report that higher serum anti-PD-1 autoantibody levels were associated with a poor prognosis in patients who received Atezo/Bev as first-line therapy,” said Dr. Akinobu Takaki from the Department of Gastroenterology and Hepatology, Okayama University who led the research team. “Notably, serum levels of anti-PD-1 autoantibody may serve as a novel potential biomarker for predicting the efficacy of immune checkpoint inhibitors in patients with HCC. Overall, our findings will bring hope to patients with liver cancer and pave the way for development of improved treatment regimens in the future.”


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.